The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Hepatitis B flares in chronic hepatitis B: Pathogenesis, natural course, and management
Open accessAbstract
Hepatitis B flare, defined as an event with abrupt rise of alanine aminotransferase (ALT) levels to >5 times the upper limit of normal during chronic hepatitis B virus (HBV) infection, is considered to be the result of a human leukocyte antigen-I restricted, cytotoxic T lymphocyte mediated immune response against HBV and its downstream mechanisms. It may occur spontaneously, during or after antiviral therapy and in the setting of immunosuppression and/or chemotherapy. The clinical spectrum of hepatitis B flares varies from asymptomatic to symptomatic and typical overt acute hepatitis, even with hepatic decompensation or failure. Flares may also occur in viraemic patients with cirrhosis with higher incidence of decompensation/mortality, hence requiring immediate antiviral therapy. An upsurge of serum HBV DNA and hepatitis B surface antigen levels usually precedes the abrupt rise of ALT levels. Rising or stable and high HBV DNA during flares represent ineffective immune clearance and further hepatocytolysis, even hepatic decompensation, may occur. Such patients require immediate antiviral therapy. In contrast, bridging hepatic necrosis and/or alpha-fetoprotein levels >100 ng/ml or decreasing HBV DNA during flares represent a more effective immune clearance and frequently leads to seroclearance of HBV DNA and/or hepatitis B e antigen with remission. If patients are non-cirrhotic and there is no concern of developing decompensation, patients may be observed for 3-6 months before deciding on the need of antiviral therapy. Severe and repeated flares are prone to develop into decompensation or lead to the development of cirrhosis, thus a timely treatment to prevent the hepatitis B flare is better than to cope with the flare. Screening, monitoring and prophylactic or pre-emptive antiviral therapy is mandatory for patients who are going to receive immunosuppressants or chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lok, A. S. F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,087
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
European Association for the Study of the Liver (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.010 · Cited by 2,925
Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B
Lau, G. K. K., Piratvisuth, T., Luo, K. X., Marcellin, P., Thongsawat, S., Cooksley, G., Gane, E., Fried, M. W., Chow, W. C., Paik, S. W., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043470 · Cited by 1,519
A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B
Chang, T.-T., Gish, R. G., de Man, R., Gadano, A., Sollano, J., Chao, Y.-C., Lok, A. S., Han, K.-H., Goodman, Z., Zhu, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051285 · Cited by 1,444
Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B
Marcellin, P., Chang, T.-T., Lim, S. G., Tong, M. J., Sievert, W., Shiffman, M. L., Jeffers, L., Goodman, Z., Wulfsohn, M. S., Xiong, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020681 · Cited by 1,336
Liaw, Y.-F., & Chu, C.-M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60207-5 · Cited by 1,218
Self-citationEntecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B
Lai, C.-L., Shouval, D., Lok, A. S., Chang, T.-T., Cheinquer, H., Goodman, Z., DeHertogh, D., Wilber, R., Zink, R. C., Cross, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051287 · Cited by 1,188
Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B
Marcellin, P., Heathcote, E. J., Buti, M., Gane, E., de Man, R. A., Krastev, Z., Germanidis, G., Lee, S. S., Flisiak, R., Kaita, K., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802878 · Cited by 1,181
Marcellin, P., Lau, G. K. K., Bonino, F., Farci, P., Hadziyannis, S., Jin, R., Lu, Z.-M., Piratvisuth, T., Germanidis, G., Yurdaydin, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040431 · Cited by 1,145
Peck, M., Craxì, A., Fried, M., & Zeuzem, S. (2013) · Cited by 1,079
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update
Liaw, Y.-F., Kao, J.-H., Piratvisuth, T., Chan, H. L. Y., Chien, R.-N., Liu, C.-J., Gane, E., Locarnini, S., Lim, S.-G., Han, K.-H., et al. (2012) · Hepatology International · doi:10.1007/s12072-012-9365-4 · Cited by 1,038
Self-citationSpecific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA
Lucifora, J., Xia, Y., Reisinger, F., Zhang, K., Stadler, D., Cheng, X., Sprinzl, M. F., Koppensteiner, H., Makowska, Z., Volz, T., et al. (2014) · Science · doi:10.1126/science.1243462 · Cited by 893
Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy
Lok, A. S. F., Liang, R. H. S., Chiu, E. K. W., Wong, K.-L., Chan, T.-K., & Todd, D. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90599-g · Cited by 827
Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B
Lai, C.-L., Gane, E., Liaw, Y.-F., Hsu, C.-W., Thongsawat, S., Wang, Y., Chen, Y., Heathcote, E. J., Rasenack, J., Bzowej, N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066422 · Cited by 773
Self-citationLok, A. S. F., & McMahon, B. J. (2001) · Hepatology · doi:10.1053/jhep.2001.29401 · Cited by 709
Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B
Hsu, Y.-S., Chien, R.-N., Yeh, C.-T., Sheen, I.-S., Chiou, H.-Y., Chu, C.-M., & Liaw, Y.-F. (2002) · Hepatology · doi:10.1053/jhep.2002.33638 · Cited by 705
Self-citationEffects of extended lamivudine therapy in Asian patients with chronic hepatitis B
Liaw, Y., Leung, N. W. Y., Chang, T., Guan, R., Tai, D., Ng, K., Chien, R., Dent, J., Roman, L., Edmundson, S., et al. (2000) · Gastroenterology · doi:10.1053/gast.2000.8559 · Cited by 689
Self-citationThe development of cirrhosis in patients with chronic type B hepatitis: A prospective study
Liaw, Y.-F., Tai, D.-I., Chu, C.-M., & Chen, T.-J. (1988) · Hepatology · doi:10.1002/hep.1840080310 · Cited by 612
Self-citationBelloni, L., Allweiss, L., Guerrieri, F., Pediconi, N., Volz, T., Pollicino, T., Petersen, J., Raimondo, G., Dandri, M., & Levrero, M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58847 · Cited by 577
Mother's little helpers: mechanisms of maternal-fetal tolerance
Trowsdale, J., & Betz, A. G. (2006) · Nature Immunology · doi:10.1038/ni1317 · Cited by 575
Liaw, Y., Gane, E., Leung, N., Zeuzem, S., Wang, Y., Lai, C. L., Heathcote, E. J., Manns, M., Bzowej, N., Niu, J., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.10.026 · Cited by 562
Self-citationControl of cccDNA function in hepatitis B virus infection
Levrero, M., Pollicino, T., Petersen, J., Belloni, L., Raimondo, G., & Dandri, M. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.05.022 · Cited by 552 · cited 1×
“1410 Journal of Hepatology 2014 and further diluted by subsequent regeneration [38], the immune mediated cytolysis of HBV-containing hepatocytes and the noncytolytic actions of CTL-secreted cytokines, including IFN-c and tumour necrosis factor (TNF)-a, in abolishing HBV gene expression and replication, may enhance the…”
BackgroundLong-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B
Hadziyannis, S. J., Tassopoulos, N. C., Heathcote, E. J., Chang, T.-T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S. G., Goodman, Z., Ma, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042957 · Cited by 531
Cooksley, W. G. E., Piratvisuth, T., Lee, S. ‐., Mahachai, V., Chao, Y. ‐., Tanwandee, T., Chutaputti, A., Chang, W. Y., Zahm, F. E., & Pluck, N. (2003) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2003.00450.x · Cited by 475
Loomba, R., Rowley, A., Wesley, R., Liang, T. J., Hoofnagle, J. H., Pucino, F., & Csako, G. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-7-200804010-00008 · Cited by 459
Dunn, C., Brunetto, M., Reynolds, G., Christophides, T., Kennedy, P. T., Lampertico, P., Das, A., Lopes, A. R., Borrow, P., Williams, K., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061287 · Cited by 421
Perrillo, R. P. (2001) · Gastroenterology · doi:10.1053/gast.2001.22461 · Cited by 421
Zhang, J.-Y., Zhang, Z., Lin, F., Zou, Z.-S., Xu, R.-N., Jin, L., Fu, J.-L., Shi, F., Shi, M., Wang, H.-F., et al. (2010) · Hepatology · doi:10.1002/hep.23273 · Cited by 371
Hadziyannis, S. J., Sevastianos, V., Rapti, I., Vassilopoulos, D., & Hadziyannis, E. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.039 · Cited by 347
Liaw, Y.-F., Chu, C.-M., Su, I.-J., Huang, M.-J., Lin, D.-Y., & Chang-Chien, C.-S. (1983) · Gastroenterology · doi:10.1016/s0016-5085(83)80114-0 · Cited by 341
Self-citationIL-10–Producing Regulatory B Cells in the Pathogenesis of Chronic Hepatitis B Virus Infection
Das, A., Ellis, G., Pallant, C., Lopes, A. R., Khanna, P., Peppa, D., Chen, A., Blair, P., Dusheiko, G., Gill, U., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103139 · Cited by 339
Song, B.-C., Suh, D. J., Lee, H. C., Chung, Y.-H., & Lee, Y. S. (2000) · Hepatology · doi:10.1053/jhep.2000.16665 · Cited by 336
Huang, Y.-H., Hsiao, L.-T., Hong, Y.-C., Chiou, T.-J., Yu, Y.-B., Gau, J.-P., Liu, C.-Y., Yang, M.-H., Tzeng, C.-H., Lee, P.-C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.5938 · Cited by 326
Cheng, A., Hsiung, C. A., Su, I., Chen, P., Chang, M., Tsao, C.-J., Kao, W.-Y., Uen, W., Hsu, C., Tien, H., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50220 · Cited by 289
Self-citationTsai, S. L., Chen, P. J., Lai, M. Y., Yang, P. M., Sung, J. L., Huang, J. H., Hwang, L. H., Chang, T. H., & Chen, D. S. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115590 · Cited by 287
Hsu, C., Tsou, H.-H., Lin, S.-J., Wang, M.-C., Yao, M., Hwang, W.-L., Kao, W.-Y., Chiu, C.-F., Lin, S.-F., Lin, J., et al. (2014) · Hepatology · doi:10.1002/hep.26718 · Cited by 277
Pérez-Alvarez, R., Díaz-Lagares, C., García-Hernández, F., Lopez-Roses, L., Brito-Zerón, P., Pérez-de-Lis, M., Retamozo, S., Bové, A., Bosch, X., Sanchez-Tapias, J.-M., et al. (2011) · Medicine · doi:10.1097/md.0b013e3182380a76 · Cited by 276
Micco, L., Peppa, D., Loggi, E., Schurich, A., Jefferson, L., Cursaro, C., Panno, A. M., Bernardi, M., Brander, C., Bihl, F., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.09.029 · Cited by 253
Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection
Lok, A. S. F., & Lai, C.-L. (1990) · Journal of Hepatology · doi:10.1016/0168-8278(90)90069-4 · Cited by 238
Management of patients with hepatitis B who require immunosuppressive therapy
Hwang, J. P., & Lok, A. S.-F. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.216 · Cited by 234
Jeng, W.-J., Sheen, I.-S., Chen, Y.-C., Hsu, C.-W., Chien, R.-N., Chu, C.-M., & Liaw, Y.-F. (2013) · Hepatology · doi:10.1002/hep.26549 · Cited by 225
Self-citationDeterminants for Sustained Hbeag Response to Lamivudine Therapy
Chien, R.-N., Yeh, C.-T., Tsai, S.-L., Chu, C.-M., & Liaw, Y.-F. (2003) · Hepatology · doi:10.1053/jhep.2003.50458 · Cited by 214
Self-citationInterleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B.
Rossol, S., Marinos, G., Carucci, P., Singer, M. V., Williams, R., & Naoumov, N. V. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119498 · Cited by 210
Jang, J. W., Choi, J. Y., Bae, S. H., Yoon, S. K., Chang, I. U., Kim, C. W., Cho, S. H., Han, J. Y., & Lee, Y. S. (2006) · Hepatology · doi:10.1002/hep.21024 · Cited by 198
Exacerbation of chronic hepatitis B infection after delivery
Ter Borg, M. J., Leemans, W. F., De Man, R. A., & Janssen, H. L. A. (2008) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2007.00894.x · Cited by 195
Lau, G. K. K., He, M., Fong, D., Bartholomeusz, A., Au, W., Lie, A. K. W., LOCARNINI, S. A., & Liang, R. H. S. (2002) · Hepatology · doi:10.1053/jhep.2002.35068 · Cited by 192
Chen, Y.-C., Chu, C.-M., & Liaw, Y.-F. (2010) · Hepatology · doi:10.1002/hep.23348 · Cited by 190
Self-citationChu, C.-M., & Liaw, Y.-F. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.03.018 · Cited by 163
Self-citationHou, J., Yin, Y.-K., Xu, D., Tan, D., Niu, J., Zhou, X., Wang, Y., Zhu, L., He, Y., Ren, H., et al. (2008) · Hepatology · doi:10.1002/hep.22075 · Cited by 160
Tan, A. T., Koh, S., Goh, W., Zhe, H. Y., Gehring, A. J., Lim, S. G., & Bertoletti, A. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.12.015 · Cited by 157
Liaw, Y., Tai, D., Chu, C., Pao, C. C., & Chen, T. (1987) · Hepatology · doi:10.1002/hep.1840070106 · Cited by 156
Self-citationEvans, A., Riva, A., Cooksley, H., Phillips, S., Puranik, S., Nathwani, A. C., Brett, S. J., Chokshi, S., & Naoumov, N. V. (2008) · Hepatology · doi:10.1002/hep.22419 · Cited by 150
Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis
Sheen, I., Liaw, Y., Tai, D., & Chu, C. (1985) · Gastroenterology · doi:10.1016/0016-5085(85)90566-9 · Cited by 138
Self-citationAntiviral therapy of chronic hepatitis B: Opportunities and challenges in Asia
Liaw, Y. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.003 · Cited by 132
Self-citationNguyen, V., Tan, P. K., Greenup, A.-J., Glass, A., Davison, S. A., Samarasinghe, D., Holdaway, S., Strasser, S. I., Chatterjee, U., Jackson, K., et al. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12726 · Cited by 120
Lim, S. G., Wai, C. T., Rajnakova, A., Kajiji, T., & Guan, R. (2002) · Gut · doi:10.1136/gut.51.4.597 · Cited by 120
Flink, H. J., Sprengers, D., Hansen, B. E., van Zonneveld, M., de Man, R. A., Schalm, S. W., & Janssen, H. L. A. (2005) · Gut · doi:10.1136/gut.2004.062208 · Cited by 119
Lee, H. W., Lee, H. J., Hwang, J. S., Sohn, J. H., Jang, J. Y., Han, K. J., Han, K. J., Park, J. Y., Kim, D. Y., Ahn, S. H., et al. (2009) · Hepatology · doi:10.1002/hep.23323 · Cited by 115
Allweiss, L., Volz, T., Lütgehetmann, M., Giersch, K., Bornscheuer, T., Lohse, A. W., Petersen, J., Ma, H., Klumpp, K., Fletcher, S. P., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.10.021 · Cited by 91
Isoniazid-rifampin-induced hepatitis in hepatitis B carriers
Wu, J., Lee, S., Yeh, P.-F., Chan, C., Wang, Y.-J., Huang, Y., Tsai, Y., Lee, P.-Y., Ting, L., & Lo, K. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90846-s · Cited by 87
Crane, M., Oliver, B., Matthews, G. V., Avihingsanon, A., Ubolyam, S., Markovska, V. C., Chang, J. J., Dore, G. J., Price, P., Visvanathan, K., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/597276 · Cited by 87
Liaw, Y., Pao, C. C., Chu, C., Sheen, I., & Mj, H. (1987) · Hepatology · doi:10.1002/hep.1840070102 · Cited by 84
Self-citationChronic hepatitis B virus (HBV) infection in pregnancy
Tan, H., Lui, H.-F., & Chow, W. C. (2008) · Hepatology International · doi:10.1007/s12072-008-9063-4 · Cited by 76
A prospective study characterizing full-length hepatitis B virus genomes during acute exacerbation
Liu, C., Chen, P., Lai, M., Kao, J., Chang, C.-F., Wu, H., Shau, W., & Chen, D. (2003) · Gastroenterology · doi:10.1053/gast.2003.50003 · Cited by 71
Chu, C., Liaw, Y., Pao, C. C., et al. (1989) · Hepatology · doi:10.1002/hep.1840090319 · Cited by 61
Self-citationJeng, W., Sheen, I., & Liaw, Y. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.02.023 · Cited by 60
Self-citationCurrent therapeutic trends in therapy for chronic viral hepatitis
Liaw, Y. (1997) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.1997.tb00520.x · Cited by 54
Self-citationVIRAL hepatitis in solid organ transplantation other than liver
Vallet‐Pichard, A., Fontaine, H., Mallet, V. O., & Pol, S. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.01.003 · Cited by 42
Liaw, Y., Pao, C. C., & Chu, C. (1988) · Liver International · doi:10.1111/j.1600-0676.1988.tb00998.x · Cited by 41
Self-citationFukuda, R., Ishimura, N., Nguyen, T., Chowdhury, A. R., Ishihara, S., Kohge, N., Akagi, S., Watanabe, M., & Fukumoto, S. (1995) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1995.tb03720.x · Cited by 40
Feng, I., Koay, L., Sheu, M., Kuo, H., Sun, C., Lee, C., Chuang, W.-L., Liao, S., Wang, S.-L., Tang, L., et al. (2006) · Journal of Biomedical Science · doi:10.1007/s11373-006-9129-z · Cited by 39
Wen-jin, Z., Chuanhui, P., Yunle, W., Lateef, S. A., & Shusen, Z. (2012) · BMC Gastroenterology · doi:10.1186/1471-230x-12-109 · Cited by 32
Zhang, N., Reijnders, J. G. P., Perquin, M., et al. (2011) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2011.01448.x · Cited by 21
Koay, L., Feng, I., Sheu, M., Kuo, H., Lin, C., Chen, J.-J., Wang, S.-L., Tang, L., & Tsai, S. (2011) · Human Immunology · doi:10.1016/j.humimm.2010.11.001 · Cited by 14
Cited by
EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure
Wendon, J., Cordoba, J., Dhawan, A., Larsen, F. S., Manns, M., Nevens, F., Samuel, D., Simpson, K. J., Yaron, I., & Bernardi, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.003 · Cited by 917
Global burden of hepatitis B virus: current status, missed opportunities and a call for action
Hsu, Y.-C., Huang, D. Q., & Nguyen, M. H. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00760-9 · Cited by 632
Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma
Hanif, H., Ali, M. J., Susheela, A. T., Khan, I. W., Luna-Cuadros, M. A., Khan, M. M., & Lau, D. T.-Y. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i2.216 · Cited by 354
Metadata
- Authors
- Chang, M.-L., & Liaw, Y.-F.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2014-12
- Volume
- 61
- Issue
- 6
- Pages
- 1407-1417
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2007113606
- Cited by
- 296
- References
- 74
- FWCI
- 13.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.